MEEI drops litigation against QLT & Novartis
Litigation proceedings initiated by the Massachusetts Eye and Ear Infirmary (MEEI) in 2001 against QLT and Novartis Ophthalmics, have been settled.
Litigation proceedings initiated by the Massachusetts Eye and Ear Infirmary (MEEI) in 2001 against QLT and Novartis Ophthalmics, have been settled.
Under the terms of the agreement, MEEI will dismiss its claim that QLT and Novatis had infringed US Patent #6,225,303 and QLT and Novartis will dismiss its counterclaims against MEEI and named MEEI researchers.
However, a further patent lawsuit, brought in 2000 by MEEI against QLT, has yet to be resolved.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
August 4th 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction
